These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 33826157)

  • 1. Validation of α-Synuclein in L1CAM-Immunocaptured Exosomes as a Biomarker for the Stratification of Parkinsonian Syndromes.
    Jiang C; Hopfner F; Berg D; Hu MT; Pilotto A; Borroni B; Davis JJ; Tofaris GK
    Mov Disord; 2021 Nov; 36(11):2663-2669. PubMed ID: 33826157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum neuronal exosomes predict and differentiate Parkinson's disease from atypical parkinsonism.
    Jiang C; Hopfner F; Katsikoudi A; Hein R; Catli C; Evetts S; Huang Y; Wang H; Ryder JW; Kuhlenbaeumer G; Deuschl G; Padovani A; Berg D; Borroni B; Hu MT; Davis JJ; Tofaris GK
    J Neurol Neurosurg Psychiatry; 2020 Jul; 91(7):720-729. PubMed ID: 32273329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuronally Derived Extracellular Vesicle α-Synuclein as a Serum Biomarker for Individuals at Risk of Developing Parkinson Disease.
    Yan S; Jiang C; Janzen A; Barber TR; Seger A; Sommerauer M; Davis JJ; Marek K; Hu MT; Oertel WH; Tofaris GK
    JAMA Neurol; 2024 Jan; 81(1):59-68. PubMed ID: 38048087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long Noncoding RNA POU3F3 and α-Synuclein in Plasma L1CAM Exosomes Combined with β-Glucocerebrosidase Activity: Potential Predictors of Parkinson's Disease.
    Zou J; Guo Y; Wei L; Yu F; Yu B; Xu A
    Neurotherapeutics; 2020 Jul; 17(3):1104-1119. PubMed ID: 32236821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α-Synuclein in Plasma-Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson's Disease.
    Stuendl A; Kraus T; Chatterjee M; Zapke B; Sadowski B; Moebius W; Hobert MA; Deuschle C; Brockmann K; Maetzler W; Mollenhauer B; Schneider A
    Mov Disord; 2021 Nov; 36(11):2508-2518. PubMed ID: 34002893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oligomeric α-synuclein and tau aggregates in NDEVs differentiate Parkinson's disease from atypical parkinsonisms.
    Meloni M; Agliardi C; Guerini FR; Zanzottera M; Bolognesi E; Picciolini S; Marano M; Magliozzi A; Di Fonzo A; Arighi A; Fenoglio C; Franco G; Arienti F; Saibene FL; Navarro J; Clerici M
    Neurobiol Dis; 2023 Jan; 176():105947. PubMed ID: 36481435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracellular Vesicles for the Diagnosis of Parkinson's Disease: Systematic Review and Meta-Analysis.
    Xylaki M; Chopra A; Weber S; Bartl M; Outeiro TF; Mollenhauer B
    Mov Disord; 2023 Sep; 38(9):1585-1597. PubMed ID: 37449706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders.
    Mondello S; Constantinescu R; Zetterberg H; Andreasson U; Holmberg B; Jeromin A
    Parkinsonism Relat Disord; 2014 Apr; 20(4):382-7. PubMed ID: 24507721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies.
    Stuendl A; Kunadt M; Kruse N; Bartels C; Moebius W; Danzer KM; Mollenhauer B; Schneider A
    Brain; 2016 Feb; 139(Pt 2):481-94. PubMed ID: 26647156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson's disease from multiple system atrophy.
    Dutta S; Hornung S; Kruayatidee A; Maina KN; Del Rosario I; Paul KC; Wong DY; Duarte Folle A; Markovic D; Palma JA; Serrano GE; Adler CH; Perlman SL; Poon WW; Kang UJ; Alcalay RN; Sklerov M; Gylys KH; Kaufmann H; Fogel BL; Bronstein JM; Ritz B; Bitan G
    Acta Neuropathol; 2021 Sep; 142(3):495-511. PubMed ID: 33991233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic Assessment of 10 Biomarker Candidates Focusing on α-Synuclein-Related Disorders.
    Schulz I; Kruse N; Gera RG; Kremer T; Cedarbaum J; Barbour R; Zago W; Schade S; Otte B; Bartl M; Hutten SJ; Trenkwalder C; Mollenhauer B
    Mov Disord; 2021 Dec; 36(12):2874-2887. PubMed ID: 34363416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Facile Impedimetric Analysis of Neuronal Exosome Markers in Parkinson's Disease Diagnostics.
    Fu Y; Jiang C; Tofaris GK; Davis JJ
    Anal Chem; 2020 Oct; 92(20):13647-13651. PubMed ID: 32945162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central Nervous System-Derived Exosomal Alpha-Synuclein in Serum May Be a Biomarker in Parkinson's Disease.
    Si X; Tian J; Chen Y; Yan Y; Pu J; Zhang B
    Neuroscience; 2019 Aug; 413():308-316. PubMed ID: 31102760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of α-synuclein in CNS-originating extracellular vesicles for Parkinsonian disorders: A systematic review and meta-analysis.
    Taha HB; Ati SS
    CNS Neurosci Ther; 2023 Dec; 29(12):3741-3755. PubMed ID: 37416941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of exosomal biomarkers and its optimal isolation and detection method for the diagnosis of Parkinson's disease: A systematic review and meta-analysis.
    Nila IS; Sumsuzzman DM; Khan ZA; Jung JH; Kazema AS; Kim SJ; Hong Y
    Ageing Res Rev; 2022 Dec; 82():101764. PubMed ID: 36273807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aggregation and beyond: alpha-synuclein-based biomarkers in synucleinopathies.
    Chopra A; Outeiro TF
    Brain; 2024 Jan; 147(1):81-90. PubMed ID: 37526295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A longitudinal study on α-synuclein in plasma neuronal exosomes as a biomarker for Parkinson's disease development and progression.
    Niu M; Li Y; Li G; Zhou L; Luo N; Yao M; Kang W; Liu J
    Eur J Neurol; 2020 Jun; 27(6):967-974. PubMed ID: 32150777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Cerebrospinal Fluid α-Synuclein Seed Amplification Assay in Progressive Supranuclear Palsy and Corticobasal Syndrome.
    Vaughan DP; Fumi R; Theilmann Jensen M; Hodgson M; Georgiades T; Wu L; Lux D; Obrocki R; Lamoureux J; Ansorge O; Allinson KSJ; Warner TT; Jaunmuktane Z; Misbahuddin A; Leigh PN; Ghosh BCP; Bhatia KP; Church A; Kobylecki C; Hu MTM; Rowe JB; Blauwendraat C; Morris HR; Jabbari E
    Mov Disord; 2024 Dec; 39(12):2285-2291. PubMed ID: 39301998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.